Limula Enters Commercial Phase of Its Cell Therapy Platform
Share this article
Vaud-Based biotech company Limula is transitioning from a technology-driven startup to a commercial entity preparing for industrial production and market deployment of LimONE, its cell therapy manufacturing platform.
After several years of development, Limula has successfully moved from vision to revenue. In early 2026, Limula engaged with eight biotech companies and clinical centers, generating its first commercial revenues and building a growing pipeline of partners committed to integrating its solution into clinical workflows.
A Breakthrough in Automated Cell Therapy Manufacturing
At the core of Limula’s innovation is LimONE, a fully closed and automated manufacturing platform designed to streamline the production of advanced cell therapies such as CAR-T treatments.
The company recently completed its first fully automated, end-to-end 7-day CAR-T cell production run on a LimONE device. The process integrates all critical manufacturing steps—T-cell selection, activation, lentiviral transduction, expansion, washing, and harvest—into a single automated workflow with minimal human intervention.
The results exceeded expectations. The system achieved over 40-fold cell expansion within seven days, alongside high transduction rates and excellent cell viability, outperforming current gold-standard solutions. These findings are expected to be submitted for peer-reviewed publication.
Beyond CAR-T therapies, Limula is exploring applications across other cell types, positioning its platform as a versatile solution for next-generation cell therapy manufacturing.
From Prototype to Industrialization
Another key achievement is the completion of the first industrial-ready device based on the released product design. The system meets user requirements and regulatory standards, enabling Limula to begin the industrialization phase and scale production.
This marks the company’s transition from a research-focused organization to an execution-driven commercial company focused on customer adoption and manufacturing readiness.
Leadership Transition to Support Growth
To support this new phase, Limula has implemented a leadership transition. Co-founder Luc Henry has stepped down as CEO after guiding the company through its foundational years. He will remain involved to ensure a smooth transition. Thomas Eaton has been appointed CEO to lead operational execution and scale the company’s commercial activities.
➡️ Source: Press Release | 📸 ©Limula. Luc Henry, Yann Pierson, Thomas Eaton.